[EN] NOVEL DIHYDROPYRIDINONE AND DIHYDROPYRIMIDINONE COMPOUNDS AND THEIR USE<br/>[FR] NOUVEAUX COMPOSÉS DIHYDROPYRIDINONE ET DIHYDROPYRIMIDINONE ET LEUR UTILISATION
申请人:UNIV LILLE II DROIT & SANTE
公开号:WO2017134188A1
公开(公告)日:2017-08-10
The present invention is directed to novel compounds of Formula I; pharmaceutically acceptable salts or solvates thereof, and their use.
本发明涉及公式I的新化合物;其药学上可接受的盐或溶剂,以及它们的用途。
[EN] NOVEL 5-AMINO-2-THIOIMIDAZOLE COMPOUNDS AND THEIR USE<br/>[FR] NOUVEAUX COMPOSÉS 5-AMINO-2-THIO-IMIDAZOLES ET LEUR UTILISATION
申请人:UNIV LILLE II DROIT & SANTE
公开号:WO2017042380A1
公开(公告)日:2017-03-16
The present invention is directed to novel compounds of formula (I) pharmaceutically acceptable salts or solvates thereof, and their use.
本发明涉及公式(I)的新化合物,其药用盐或溶剂,以及它们的用途。
Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof
申请人:Statens Serum Institut
公开号:US20040086949A1
公开(公告)日:2004-05-06
The present invention relates to a method for preparing a ligand presenting assembly (LPA), an LPA, an immunological composition and a vaccine. The invention further relates to a method for generating antibodies, a kit for use in diagnosis and use of an LPA for preparing a pharmaceutical composition.
The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,I1 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to the use of said compounds for production of a medicament for treatment of conditions and diseases, wherein NCAM and/or FGFR play a prominent role.
[EN] NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY<br/>[FR] COMPOSITIONS DE NANOMATÉRIAU, SYNTHÈSE ET ASSEMBLAGE
申请人:RHODE ISLAND HOSPITAL
公开号:WO2016081522A1
公开(公告)日:2016-05-26
Compositions or an assembly of a series of biomimetic compounds include chemical structures that mimic or structurally resemble a nucleic acid base pair. Complexes of nanotubes and agents are useful to deliver agents into the cells or bodily tissues of individuals for therapeutic and diagnostic purposes. Exemplary compounds include those of Formula (I), (III), (V) or (VII), or of Formula (II), (IV), (VI) or (VIII).